High Growth Tech Stocks To Watch In The United States
Over the last 7 days, the market has remained flat, but it is up 23% over the past year with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks that align with these optimistic projections can be crucial for investors seeking robust returns.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| TG Therapeutics | 28.62% | 43.05% | ★★★★★★ |
| Sarepta Therapeutics | 24.22% | 44.94% | ★★★★★★ |
| Super Micro Computer | 20.62% | 27.13% | ★★★★★★ |
| Ardelyx | 27.44% | 65.50% | ★★★★★★ |
| G1 Therapeutics | 27.57% | 57.75% | ★★★★★★ |
| Invivyd | 42.91% | 70.39% | ★★★★★★ |
| Amicus Therapeutics | 20.45% | 61.85% | ★★★★★★ |
| Clene | 73.06% | 62.58% | ★★★★★★ |
| Seagen | 22.57% | 71.80% | ★★★★★★ |
| ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 249 stocks from our US High Growth Tech and AI Stocks screener.
Let's explore several standout options from the results in the screener.
Appian
Simply Wall St Growth Rating: ★★★★★☆
Overview: Appian Corporation is a software company that offers a low-code design platform across the United States, Mexico, Portugal, and internationally, with a market cap of $2.35 billion.
Operations: Appian Corporation generates revenue primarily from its software and programming segment, amounting to $578.70 million. The company operates internationally, including in the United States, Mexico, and Portugal.
Appian's strategic focus on process automation and low-code development is driving notable partnerships and client adoptions, such as the collaboration with Outsourcing Technology Co. Ltd. in Japan, which reduced workload by 25%. Revenue for Q2 2024 reached $146.45 million, a 14.65% increase from the previous year, despite a net loss of $43.59 million. The company’s R&D expenses have been significant; in the last fiscal year alone, Appian invested approximately $100 million to enhance its platform capabilities. Software firms are increasingly moving to SaaS models, ensuring recurring revenue from subscriptions; Appian's AI Process Platform exemplifies this trend by offering integrated solutions like the Victorian Office of Public Prosecutions' new matter management system that anticipates a productivity gain of over 10% annually. Future prospects appear promising with forecasted annual revenue growth at 10.3%, outpacing the broader US market's expected growth rate of 8.7%.
-
Click to explore a detailed breakdown of our findings in Appian's health report.
-
Explore historical data to track Appian's performance over time in our Past section.
Amicus Therapeutics
Simply Wall St Growth Rating: ★★★★★★
Overview: Amicus Therapeutics, Inc. is a biotechnology company dedicated to discovering, developing, and delivering medicines for rare diseases with a market cap of $3.44 billion.